Last reviewed · How we verify
Dose -mFOLFIRINOX
mFOLFIRINOX is a combination chemotherapy regimen that uses multiple cytotoxic agents to damage cancer cell DNA and inhibit cell division.
mFOLFIRINOX is a combination chemotherapy regimen that uses multiple cytotoxic agents to damage cancer cell DNA and inhibit cell division. Used for Metastatic pancreatic cancer (first-line treatment).
At a glance
| Generic name | Dose -mFOLFIRINOX |
|---|---|
| Sponsor | Pancreatic Cancer Action Network |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
mFOLFIRINOX combines 5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin. 5-FU and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis; irinotecan inhibits topoisomerase I to prevent DNA unwinding; and oxaliplatin forms DNA cross-links. Together, these agents create multiple mechanisms of cytotoxic stress on rapidly dividing cancer cells.
Approved indications
- Metastatic pancreatic cancer (first-line treatment)
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Fatigue
- Peripheral neuropathy
- Anemia
- Thrombocytopenia
Key clinical trials
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2, PHASE3)
- A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (PHASE1)
- A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (PHASE1)
- Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer (PHASE2)
- A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC (PHASE2)
- Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (PHASE2, PHASE3)
- Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (PHASE2)
- MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dose -mFOLFIRINOX CI brief — competitive landscape report
- Dose -mFOLFIRINOX updates RSS · CI watch RSS
- Pancreatic Cancer Action Network portfolio CI